Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Lynparza recommended in EU for early breast cancer
Preheader (150)Lynparza recommended for approval in the EU by CHMP as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast
Typography
Arial
Colors
Text Analysis
Body Words233
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px814 px
X-Spam Score-4.4
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEarly Morning

Lynparza recommended in EU for early breast cancer

Lynparza recommended for approval in the EU by CHMP as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast
Lynparza recommended in EU for early breast cancer